A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of MDR-001 Administered Orally Over 52 Weeks in Participants With Overweight or Obesity (MOBILE)
Latest Information Update: 16 Jan 2026
At a glance
- Drugs MDR-001 (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms MOBILE
- Sponsors MindRank
Most Recent Events
- 06 Jan 2026 According to a Mindrank media release, this trial is led by Professor Linong Ji, Director of Endocrinology and Metabolism department at Peking University People's Hospital and the Leading Principal Investigator for the MDR-001 clinical program.
- 15 Dec 2025 New trial record